AI-generated research brief — verify at source
SAMe 400 mg Daily Fails to Reduce Plasma P-Tau217 in Alzheimer’s Disease Trial
A six-month placebo-controlled trial found no statistically significant reduction in plasma phosphorylated tau (p-tau217) among people with Alzheimer’s disease taking SAMe 400 mg daily, with a standardized mean difference of 37.58 (95% CI −32.61 to 107.76; p = 0.288) that, if anything, trended in the wrong direction. The wide confidence interval means the true effect remains highly uncertain, and the result neither confirms nor rules out a biologically meaningful impact at this dose.
What Was Studied
The trial investigated whether oral supplementation with S-adenosyl methionine (SAMe), a metabolite implicated in tau dephosphorylation and other neuronal pathways, could lower plasma p-tau217 concentrations — a biomarker of tau pathology — in individuals diagnosed with Alzheimer’s disease. The rationale was grounded in observations that SAMe availability is reduced in the AD brain, raising the possibility that replenishing it could attenuate abnormal tau phosphorylation.
How It Was Studied
This was a phase 2, multicenter, randomized, double-blind, placebo-controlled trial conducted across multiple sites and registered with the Australian New Zealand Clinical Trials Registry. Sixty-three participants with a clinical diagnosis of mild cognitive impairment or dementia due to Alzheimer’s disease were enrolled and randomly assigned to receive either SAMe at 400 mg per day or an identical-appearing placebo for 180 days. The primary endpoint was the change in plasma p-tau217 concentration from baseline to end of treatment, with secondary endpoints covering safety, tolerability, and cognitive outcomes.
What Was Observed
- No significant difference in plasma p-tau217 between groups: The SAMe group showed a mean percentage increase in plasma p-tau217 of 53.22 (SD 159.19), compared with 25.34 (SD 94.83) in the placebo group — a standardized mean difference of 37.58 (95% CI −32.61 to 107.76; p = 0.288), indicating no statistically meaningful separation between arms. Notably, both groups showed an increase rather than a decrease in tau levels over the study period.
- No significant differences on safety or tolerability measures: SAMe was described as safe and well tolerated at the dose studied, with no significant adverse safety signals detected relative to placebo. Secondary safety endpoints did not differentiate the two groups in any clinically meaningful way.
- No significant cognitive benefit observed: Secondary cognitive outcome measures also showed no significant differences between the SAMe and placebo groups over the 180-day treatment period, consistent with the null primary endpoint.
Why This Matters
SAMe has attracted therapeutic interest in Alzheimer’s disease specifically because its availability is reportedly diminished in the AD brain and because it participates in pathways relevant to tau biology. This trial represents one of the first controlled human tests of SAMe supplementation as a disease-modifying strategy, and the null result at this dose and duration directly challenges the assumption that oral SAMe at 400 mg daily is sufficient to engage the target mechanism in a clinically detectable way. The finding does not invalidate the underlying biological rationale but does suggest that this particular dosing regimen cannot be carried forward without modification.
How to Read This Result
Given the small sample of 63 participants, a treatment duration of only six months, and a confidence interval that spans both potentially beneficial and potentially harmful effect sizes, this trial was underpowered to draw definitive conclusions, and the neutral result should be interpreted as uninformative about the true biological potential of SAMe rather than as a firm refutation.
Limitations
The study enrolled only 63 participants, substantially limiting statistical power to detect modest but meaningful effects on p-tau217. The treatment duration of 180 days may be insufficient for a disease-modifying signal to emerge in a slowly progressive condition like Alzheimer’s. Only a single fixed dose of 400 mg daily was evaluated, leaving open the possibility that higher doses or alternative formulations could produce different outcomes. As a result, these findings cannot be generalised to other doses, treatment durations, or patient subgroups.